TCL Archive The Line Item for Cancer Centers and SPOREs to Remain Flat, Near $598 Million for the 2013 Fiscal Year April 20, 2012
TCL Archive FDA IND Approval Of New Cancer Drug Is First Based On Phase 1 Clinical Trials In Europe December 5, 1986
